Patent Law Weblog
recent posts
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
about
Category: Patent Legislation
-
By Donald Zuhn — Last Tuesday, CongressDaily reported that Senate Judiciary Chairman Patrick Leahy (D-VT) (at right) and ranking member Arlen Specter (R-PA) have indicated that patent reform will be a top priority for the new session. Coalition for Patent Fairness lobbyist Steve Elmendorf told the publication that he expects to begin working…
-
By Donald Zuhn — In an article posted on the American.com website (the online version of The American magazine) on Tuesday, Dr. Aparna Mathur (at right), a Research Fellow at the American Enterprise Institute for Public Policy Research, argues that now is the time to begin lobbying against the patent reform bill that…
-
By Donald Zuhn — In an op-ed piece in today’s Wall Street Journal, L. Gordon Crovitz opines that Congress’ failure to enact patent reform this year has undermined the Constitutional mandate to encourage innovation (see "Patent Gridlock Suppresses Innovation"). The fault for our flawed system, according to Mr. Crovitz, rests with Congress, which…
-
By Donald Zuhn — Last week, the mainstream media turned its attention to the lobbying efforts of biotechnology and pharmaceutical companies. The impetus for this increased coverage was a report on lobbying issued by the Center for Public Integrity (CPI). The CPI, which describes itself as a nonprofit, non-partisan, and non-advocacy organization dedicated…
-
By Donald Zuhn — For the past few months, Patent Docs has been following and reporting on biotech and pharma lobbying efforts. Our interest in this topic stems from the push by Congress over the past year to pass patent reform and follow-on biologics legislation, and corresponding efforts by corporations and organizations during…
-
By Kevin E. Noonan — In 2001, The Medicines Company failed to file a patent term extension application for its anticoagulant drug Angiomax® (bivalirudin) within the 60-day time limit set forth under 35 U.S.C. § 156(d)(1); the application was filed one day late. Since that time, there have been efforts to remedy this…
-
By Donald Zuhn — In February, the House Subcommittee on Courts, the Internet, and Intellectual Property held an oversight hearing on the U.S. Patent and Trademark Office. The Subcommittee heard statements from Jon Dudas, the Undersecretary of Commerce for Intellectual Property and Director of U.S. Patent and Trademark Office; Robin Nazzaro, the Director…
-
By Donald Zuhn — Last month, we reported on the lobbying expenditures for a number of biotech and pharmaceutical companies in the first quarter of 2008. Included on our list were Cephalon, Inc., which spent $512,000, Abbott Laboratories, which spent $880,000, and Amgen Inc., which spent $2.5 million. That list continues to grow…
-
By Kevin E. Noonan — Among the many things "wrong" with U.S. patent law, few outside the profession (meaning few among the cadre of gadflies, pundits, careerists, and those grinding their different shades of political and rhetorical axes against current patent law) focus on one of the real problems: the varying and inconsistent…
-
By Donald Zuhn — The Senate patent reform bill may or may not be dead (see "Bush Administration Continues Attempt to Destroy U.S. Patent System"). However, if the bill’s time has indeed come and gone (at least as far as the 110th Congress is concerned), its passing will be due in no small…
Patent Docs 